Biomedical subjects

C L Wiseman

Publications and source records attributed to C L Wiseman.

4 recordsLinked to original sources

PubMed1979

Electrocardiographic changes after adriamycin chemotherapy.

The electrocardiograms of 146 patients with metastatic carcinoma of the breast were reviewed before, during, and after the patients received Adriamycin (Doxorubicin) chemotherapy (AD). The most significant electrocardiographic change occurred in the amplitude of the QRS voltage. Seven patients developed cardiomyopathy after AD and showed a significant decrease in QRS voltage. This decrease, however, was more severe at the onset of congestive heart failure that at conclusion of Adriamycin. In 35 patients with pleural effusion, there was an inverse relation between the extent of the effusion and the amplitude of QRS voltage in the absence of congestive heart failure. These results indicate that 1) the sudden and relatively severe decrease in QRS voltage with the onset of CHF limits the value of this ECG criterion for predicting early Adriamycin toxicity, and 2) caution should be exercised in the interpretation of QRS voltage changes in patients with significant pleural effusion.

Breast Neoplasms↗

PubMed1979

Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer.

Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5-FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristing 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.

Adult↗

PubMed1979

A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line.

Pleural effusion was obtained from a 51-year-old black woman who had breast adenocarcinoma and had received chemotherapy and radiation therapy after a radical mastectomy. Cytogenetic and isoenzymic analyses of the cells were performed within a few hours of obtaining the sample. Similar analyses were also done with a cell line established from this effusion. The stemline chromosome number was 35, one of the lowest in human neoplasms. In addition to a marker chromosome involving 1q, which is common in human breast tumors, we found several other marker chromosomes whose G-banding patterns were similar to some of the typical HeLa markers. Genetic signature analysis of 15 isoenzyme loci revealed that 13 were identical to those of HeLa. Both HeLa and the cell line described here express glucose-6-phosphate dehydrogenase type a, yet they were derived from heterozygotic individuals (ab). Our data indicate the necessity to extensive cytogenetic and biochemical analysis before conclusions are made that cell lines are actually intercell-line contaminants.

Adenocarcinoma↗

PubMedDate not supplied

Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.

Fifty-three patients with metastatic breast carcinoma were randomized to treatment with hexamethylmelamine (HMM) as a single agent versus a three-drug reimen of HMM, vincristine, and mitomycin C (HOM). All patients had received prior treatment with 5-fluorouracil, Adriamycin, and cyclophosphamide with or without methotrexate. HMM alone was used in a dose of 300 mg/m2/day x 14 days every 21 days. In the HOM regimen, the HMM dose was 200 mg/m2/day x 21 days, the vincristine dose was 1.5 mg on Days 1, 8, and 15, and the mitomycin C dose was 12 mg/m2 once every 6 weeks. No objective responses were observed with HMM in 15 evaluable patients. The HOM regimen resulted in five partial responses among the 27 evaluable patients. Gastrointestinal toxicity was the limiting toxicity of HMM, and thrombocytopenia was the major toxicity of the HOM regimen.

Adult↗